Boston Settles Patent Disputes With Johnson & Johnson

Boston Scientific has announced the settlement of more than a dozen lawsuits involving Johnson & Johnson, including the Palmaz-NIR suit.

The company said that all the disputes involved intellectual property in the interventional cardiology arena. In connection with the settlement, Boston Scientific will make a payment of $716m to Johnson & Johnson. The settlement payment is within Boston Scientific’s existing reserve for the Palmaz-NIR suit and will be made from existing cash on hand.

The settlement includes cross licenses for all the patents in the suits, other than the Palmaz patent, which has expired.

Ray Elliott, president and chief executive officer of Boston Scientific, said: “We are pleased we have been able to significantly reduce the amount of outstanding litigation we have with Johnson & Johnson. We continue to work with them to resolve other outstanding matters.”